NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer
Nature Genetics2008Vol. 40(7), pp. 844–853
Citations Over TimeTop 10% of 2008 papers
Rainer Fagerholm, Barbara Hofstetter, Johanna Tommiska, Kirsimari Aaltonen, Radek Vrtěl, Kirsi Syrjäkoski, Anne Kallioniemi, Outi Kilpivaara, Arto Mannermaa, Veli‐Matti Kosma, Matti Uusitupa, Matti Eskelinen, Vesa Kataja, Kristiina Aittomäki, Karl von Smitten, Päivi Heikkilä, Jiri Lukas, Kaija Holli, Jiřina Bártková, Carl Blomqvist, Jiří Bártek, Heli Nevanlinna
Related Papers
- → Epirubicin Versus Doxorubicin: Which Is the Anthracycline of Choice for the Treatment of Breast Cancer?(2003)94 cited
- → Adjuvant anthracycline in breast cancer. Improved outcome in premenopausal patients following substitution of methotrexate in the CMF Combination with epirubicin(1999)62 cited
- [Acute pulmonary edema during general anesthesia in a young woman treated with epirubicin].(1995)
- → P5-13-20: TOP2A Amplification Have Associated with Response to Anthracycline-Based Preoperative Chemotherapy in Primary Breast Cancer.(2011)
- Prospective Randomized Controlled Study of Cardiopretective Effect of Dexrazoxane on the Female Breast Cancer Patients with Postoperative Chemotherapy(2012)